France’s Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around US$2.5 billion as it seeks to beef up its immuno-oncology pipeline.
France’s Sanofi to buy Synthorx for US$2.5 billion
France’s Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around US$2.5 billion as it seeks to beef up its immuno-oncology pipeline.